All In Biotech

Drug Trial Radar · NCT04422912

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 29, 2020

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
Cabaletta BioIndustry
Sponsor type
Industry
First posted
Jun 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris

Conditions

  • Pemphigus Vulgaris

Interventions

  • DSG3-CAARTBiological

    Intravenous infusions of DSG3-CAART alone at different doses and different fractionations, with or without intravenous immunoglobulin, cyclophosphamide, and/or fludarabine.

  • CABA-201Biological

    Single intravenous infusion of CABA-201 at escalating doses, with or without preconditioning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events, including Dose Limit ToxicityTime frame: 3 months
  2. For CABA-201 Sub-study: To evaluate adverse events reported by subjectsTime frame: Up to 28 days after CABA-201 infusion

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University, Dept. of Dermatology

    Redwood City, California · Recruiting

  • UC Davis, Dept. of Dermatology

    Sacramento, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Mount Sinai - Icahn School of Medicine

    New York, New York · Withdrawn

  • Columbia University

    New York, New York · Recruiting

  • University of North Carolina, Department of Dermatology

    Chapel Hill, North Carolina · Withdrawn

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • UT Southwestern Medical Center, Dept. of Dermatology

    Dallas, Texas · Recruiting

  • MD Anderson Texas Medical Center

    Houston, Texas · Recruiting

  • University of Washington

    Seattle, Washington · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.